Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
17.04
+0.25 (1.52%)
At close: May 12, 2025, 4:00 PM
17.04
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 38.33, with a low estimate of 35 and a high estimate of 44. The average target predicts an increase of 124.94% from the current stock price of 17.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Castle Biosciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Maintains $40 → $35 | Strong Buy | Maintains | $40 → $35 | +105.40% | May 6, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $42 → $37 | Strong Buy | Maintains | $42 → $37 | +117.14% | May 6, 2025 |
| Baird | Baird | Buy Maintains $36 → $37 | Buy | Maintains | $36 → $37 | +117.14% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $41 | Buy | Reiterates | $41 | +140.61% | Jan 2, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $37 → $44 | Buy | Maintains | $37 → $44 | +158.22% | Nov 6, 2024 |
Financial Forecast
Revenue This Year
294.96M
from 332.07M
Decreased by -11.18%
Revenue Next Year
304.21M
from 294.96M
Increased by 3.14%
EPS This Year
-1.61
from 0.62
EPS Next Year
-1.86
from -1.61
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 306.5M | 328.4M | 363.2M | ||
| Avg | 295.0M | 304.2M | 332.7M | ||
| Low | 281.7M | 269.9M | 302.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.7% | 11.4% | 19.4% | ||
| Avg | -11.2% | 3.1% | 9.4% | ||
| Low | -15.2% | -8.5% | -0.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.14 | -1.07 | -1.11 | ||
| Avg | -1.61 | -1.86 | -1.70 | ||
| Low | -2.25 | -2.57 | -2.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.